ClinicalTrials.gg
CompletedNCT01855074Updated Aug 14, 2013Results posted

An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders

A Phase 4 interventional study of Risperidone in Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder, sponsored by Janssen-Cilag Ltd.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-14.

Sponsored by Janssen-Cilag Ltd. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
78th of 123
80 · median 100
Started
2007
with 6 others
Phase 4
63 of 127
2 open now
Registered
85th of 127
by date

Among the 127 studies testing risperidone in Schizophrenia, this one is the 78th largest by enrollment of the 123 interventional ones that give a count, is one of 7 that started in 2007, is one of 63 in phase 4, and was the 85th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self), schizophreniform or schizoaffective disorders (disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations).

Read the detailed description

This is an open-label (all people know the identity of the intervention), longitudinal (participants are followed over time with continuous or repeated monitoring of risk factors or health-outcomes), non-randomized (a clinical trial in which the participants are not assigned by chance to different treatment groups), single-center study to evaluate the efficacy and safety of long acting microspheres of risperidone in adult participants with schizophrenia, schizophreniform or schizoaffective disorders. The duration of this study will be 12 months and duration of treatment will be 6 months. The study will include 4 visits: Baseline, and 3 follow-up visits including Week 4, 12 and 26. All eligible participants will be treated with risperidone 25 milligram (mg) intramuscular injection (injection of a substance into a muscle) for every two weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics (agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect) will be initiated with higher doses of risperidone. Doses will be adjusted according to the response of the treatment. Efficacy and safety of the participants will be primarily evaluated by Positive and Negative Syndromes Scale (PANSS) and Extrapyramidal Symptom Rating Scale (ESRS), respectively. Participants' quality of life and safety will be monitored throughout the study.

03

Conditions studied

  • Schizophrenia
  • Schizophreniform Disorder
  • Schizoaffective Disorder

Keywords

  • Schizophrenia
  • Schizophreniform Disorder
  • Schizoaffective Disorder
  • Risperidone
  • Risperdal consta
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatically stable participants defined as a) participants with treatment on outpatient and inpatient basis for at least 4 weeks before entering the study, and b) Positive and Negative Syndrome Scale (PANSS) Positive Subscale Score less than or equal to (\<= ) 3 (1-7), including conceptual disorganization, suspicion, hallucinatory conduct and delirium (state of violent mental agitation)
  • Participants under antipsychotic treatment with extrapyramidal symptoms, persistent negative symptoms or lack of adherence defined as irregular administration of medication in the last 2 weeks
  • Participants who have given their in writing, or at least, by their family member or personal representative

Exclusion criteria

Exclusion Criteria:

  • Participants taking first antipsychotic treatment in his/her life
  • Participants with any other psychotic disorder different to the previously mentioned in the inclusion criteria
  • Pregnant or nursing women
  • History of neuroleptic malignant syndrome (potentially fatal syndrome associated primarily with the use of antipsychotic drugs and clinical features include diffuse muscle rigidity, tremor, high fever) or current symptoms of tardive dyskinesia (a neurological disorder characterized by involuntary movements of the face and jaw)
  • Participants with known intolerance or lack of response to risperidone
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Risperidone

    Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.

    Drug: Risperidone

Interventions

  • Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening. Change at Week 26 score is calculated as Baseline score minus Week 26 score.

    Time frame: Baseline and Week 26

Secondary outcomes

  1. Clinical Global Impressions (CGI) - Disease Severity Score

    The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants", higher scores indicate worsening.

    Time frame: Baseline and Week 26

  2. Short Form-36 (SF-36) - Quality of Life Score

    The SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: vitality, physical function, social function, physical role, emotional role, bodily pain, general health, mental health. Each item is scored on a scale ranging from 0-100 (100=highest level of functioning).

    Time frame: Baseline and Week 26

  3. Global Assessment of Functioning (GAF) Score

    The GAF is a 100-point tool to measure overall psychological, social and occupational functioning of adults. The higher score range (91 to 100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1 to 10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.

    Time frame: Baseline and Week 26

  4. Patient Satisfaction With Treatment

    Participants' were assessed for their satisfaction with the current antipsychotic treatment on a 5-point scale/questionnaire: very good, good, reasonable, moderate or poor.

    Time frame: Baseline and Week 26

  5. Extrapyramidal Symptom Rating Scale (ESRS) Score

    An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, absent) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.

    Time frame: Baseline and Week 26

07

Results

Posted Jul 25, 2013
Limitations and caveats
The planned sample size was not reached and a high dropout rate of participants was observed. Due to the high number of protocol violations, analysis was performed as intention-to-treat instead of per protocol as was planned.

Participant flow

Participant flow — Overall Study
MilestoneRisperidone
Started80
Treated79
Completed66
Not completed14
Withdrew: Adverse event1
Withdrew: Lost to follow-up4
Withdrew: Withdrawal by subject8
Withdrew: Started but not treated1

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening. Change at Week 26 score is calculated as Baseline score minus Week 26 score.

Time frame:
Baseline and Week 26
Reported as:
Mean · Units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26
Units on a scaleRisperidone
Baseline (n=78)68.9 ± 15.8
Change at Week 26 (n=66)28.1 ± 17.1
SecondaryClinical Global Impressions (CGI) - Disease Severity Score

The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants", higher scores indicate worsening.

Time frame:
Baseline and Week 26
Reported as:
Mean · Units on a scale
Clinical Global Impressions (CGI) - Disease Severity Score
Units on a scaleRisperidone
Baseline (n=78)4.2 ± 4.0
Week 26 (n=66)2.9 ± 3.0
SecondaryShort Form-36 (SF-36) - Quality of Life Score

The SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: vitality, physical function, social function, physical role, emotional role, bodily pain, general health, mental health. Each item is scored on a scale ranging from 0-100 (100=highest level of functioning).

Time frame:
Baseline and Week 26
Reported as:
Mean · Units on a scale
Short Form-36 (SF-36) - Quality of Life Score
Units on a scaleRisperidone
Baseline; Physical function (n=78)78.3 ± 21.7
Week 26; Physical function (n=66)90.5 ± 13.8
Baseline; Physical role (n=78)41.0 ± 46.5
Week 26; Physical role (n=66)75.4 ± 41.0
Baseline; Body pain (n=78)86.2 ± 19.8
Week 26; Body pain (n=66)94.7 ± 11.8
Baseline; General health (n=78)51.7 ± 18.3
Week 26; General health (n=66)67.8 ± 12.0
Baseline; Vitality (n=78)51.7 ± 16.8
Week 26; Vitality (n=66)58.6 ± 11.5
Baseline; Social function (n=78)49.0 ± 20.4
Week 26; Social function (n=66)74.1 ± 18.1
Baseline; Emotional role (n=78)32.1 ± 46.0
Week 26; Emotional role (n=66)73.2 ± 42.3
Baseline; Mental health (n=78)50.7 ± 13.8
Week 26; Mental health (n=66)59.9 ± 12.8
SecondaryGlobal Assessment of Functioning (GAF) Score

The GAF is a 100-point tool to measure overall psychological, social and occupational functioning of adults. The higher score range (91 to 100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1 to 10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.

Time frame:
Baseline and Week 26
Reported as:
Mean · Units on a scale
Global Assessment of Functioning (GAF) Score
Units on a scaleRisperidone
Baseline (n=78)56.5 ± 14.2
Week 26 (n=66)69.4 ± 11.7
SecondaryPatient Satisfaction With Treatment

Participants' were assessed for their satisfaction with the current antipsychotic treatment on a 5-point scale/questionnaire: very good, good, reasonable, moderate or poor.

Time frame:
Baseline and Week 26
Reported as:
Number · Participants
Patient Satisfaction With Treatment
ParticipantsRisperidone
Baseline; Very good (n=78)2
Week 26; Very good (n=66)16
Baseline; Good (n=78)13
Week 26; Good (n=66)40
Baseline; Moderate (n=78)42
Week 26; Moderate (n=66)10
Baseline; Poor (n=78)19
Baseline; Very poor (n=78)1
Baseline; No available (n=78)1
SecondaryExtrapyramidal Symptom Rating Scale (ESRS) Score

An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, absent) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.

Time frame:
Baseline and Week 26
Reported as:
Mean · Units on a scale
Extrapyramidal Symptom Rating Scale (ESRS) Score
Units on a scaleRisperidone
Baseline12.9 ± 9.6
Week 269.2 ± 5.1

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risperidone—1/79 (1.3%)1/79 (1.3%)
Most frequent serious events
Most frequent serious events
EventRisperidone
Psychotic disorderPsychiatric disorders1/79
Most frequent other events
Most frequent other events
EventRisperidone
Extrapyramidal disorderNervous system disorders1/79

Baseline characteristics

Age Continuous
Age Continuous(Years)Risperidone
Mean43.0 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Risperidone
Female32
Male47
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2013
First posted
May 16, 2013
Start
Nov 2007
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Jul 25, 2013
Last update
Aug 14, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01855074
Lead sponsor
Janssen-Cilag Ltd.
Responsible party
Sponsor
First posted
May 16, 2013
Start date
Nov 2007
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Jul 25, 2013
Last update
Aug 14, 2013

Study contacts

Janssen-Cilag Ltd. Clinical trial
study director · Janssen-Cilag Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion